MNPR
Monopar Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$356.36M
P/E Ratio
—
EPS
$-1.85
Beta
1.66
52W High
$105.00
52W Low
$28.40
50-Day MA
$55.71
200-Day MA
$62.80
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -14.20% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $20.59 |
| Price-to-Book | 2.59 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $6.69M |
| Float | $4.40M |
| % Insiders | 23.69% |
| % Institutions | 83.11% |
Historical Volatility
HV 10-Day
54.85%
HV 20-Day
52.39%
HV 30-Day
50.05%
HV 60-Day
53.48%
HV Rank
11.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($112.79 target)
4
Strong Buy10
BuyData last updated: 5/2/2026